Poorly Differentiated Neuroendocrine Carcinoma in a Perigastric Lymph Node from an Unknown Primary Site
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Neuroendocrine carcinomas from an unknown primary site are uncommon. The authors report on a case of neuroendocrine carcinoma in a perigastric lymph node (LN) with no primary site. A 52-year-old male patient with early gastric adenocarcinoma underwent treatment by endoscopic submucosal dissection, and, six months later, findings on a computed tomographic scan of the abdomen revealed a LN enlargement measuring 2.0 cm in the perigastric region. The patient underwent subtotal gastrectomy and regional LN dissection under a suggestive preoperative diagnosis of gastric adenocarcinoma with LN metastasis. However, microscopically, no residual tumor was found in the stomach, and the perigastric LN showed poorly differentiated neuroendocrine carcinoma (PDNEC). After an extensive workup, no primary site was identified. The patient also received four cycles of etoposide and cisplatin. Despite its extremely rare incidence, this case suggests that PDNEC of an unknown primary site is limited to a single site, and that resection should be considered in combination with chemotherapy.
Abstract
Neuroendocrine carcinomas from an unknown primary site are uncommon. The authors report on a case of neuroendocrine carcinoma in a perigastric lymph node (LN) with no primary site. A 52-year-old male patient with early gastric adenocarcinoma underwent treatment by endoscopic submucosal dissection, and, six months later, findings on a computed tomographic scan of the abdomen revealed a LN enlargement measuring 2.0 cm in the perigastric region. The patient underwent subtotal gastrectomy and regional LN dissection under a suggestive preoperative diagnosis of gastric adenocarcinoma with LN metastasis. However, microscopically, no residual tumor was found in the stomach, and the perigastric LN showed poorly differentiated neuroendocrine carcinoma (PDNEC). After an extensive workup, no primary site was identified. The patient also received four cycles of etoposide and cisplatin. Despite its extremely rare incidence, this case suggests that PDNEC of an unknown primary site is limited to a single site, and that resection should be considered in combination with chemotherapy.
참고문헌 (10)
- Hainsworth JD, "Poorly differentiated neuroendocrine carcinoma of unknown primary site : a newly recognized clinicopathologic entity", Ann Intern Med, 109, pp.364~371 (1988)
- Spigel DR, "Neuroendocrine carcinoma of unknown primary site", Semin Oncol, 36, pp.52~59 (2009)
- Bajetta E, "Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment?", Ann Oncol, 16, pp.1374~1380 (2005)
- Hainsworth JD, "Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma : a Minnie Pearl Cancer Research Network Study", J Clin Oncol, 24, pp.3548~3554 (2006)
- Boghossian V, "Neuroendocrine(Merkel cell)carcinoma of the retroperitoneum with no identifiable primary site", World J Surg Oncol, 5, pp.117~ (2007)
- Hisamori S, "A case of long-term recurrence-free poorly differentiated neuroendocrine carcinoma of lymph nodes treated by surgical resection without any chemotherapy", Int J Clin Oncol, 15, pp.493~496 (2010)
- Kuwabara H, "Nodal neuroendocrine(Merkel cell)carcinoma without an identifiable primary tumor", Acta Cytol, 47, pp.515~517 (2003)
- Ueda J, "Pancreaticoduodenal lymph node metastasis of neuroendocrine carcinoma of unknown primary associated with duodenal carcinoma", Nihon Shokakibyo Gakkai Zasshi, 107, pp.1941~1946 (2010)
- Mitry E, "Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin", Br J Cancer, 81, pp.1351~1355 (1999)
- Fjallskog ML, "Treatment with cisplatin and etoposide in patients with neuroendocrine tumors", Cancer, 92, pp.1101~1107 (2001)